Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study.
Acromegaly; pathological subtypes
Biochemical remission
Medical response
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
16 Sep 2021
16 Sep 2021
Historique:
received:
14
05
2021
accepted:
28
08
2021
entrez:
17
9
2021
pubmed:
18
9
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Regarding the inconclusive results of previous investigations, this study aimed to determine the association between pathology, as a possible predictor, with remission outcomes, to know the role of pathology in the personalized decision making in acromegaly patients. A retrospective cohort study was performed on the consecutive surgeries for growth hormone (GH) producing pituitary adenomas from February 2015 to January 2021. Seventy-one patients were assessed for granulation patterns and prolactin co-expression as dual staining adenomas. The role of pathology and some other predictors on surgical remission was evaluated using logistic regression models. Among 71 included patients, 34 (47.9%) patients had densely granulated (DG), 14 (19.7%) had sparsely granulated (SG), 23 (32.4%) had dual staining pituitary adenomas. The remission rate was about 62.5% in the patients with SG and DG adenomas named single staining and 52.2% in dual staining groups. Postoperative remission was 1.53-folds higher in the single staining adenomas than dual staining-one (non-significant). The remission rate was doubled in DG group compared to two other groups (non-significant). By adjusting different predictors, cavernous sinus invasion and one-day postoperative GH levels decreased remission rate by 91% (95% CI: 0.01-0.67; p = 0.015) and 64% (95% CI: 0.19-0.69; p < 0.001), respectively. Responses to the medications were not significantly different among three groups. Various pathological subtypes of pituitary adenomas do not appear to have a predictive role in estimating remission outcomes. Cavernous sinus invasion followed by one-day postoperative GH is the strongest parameter to predict biochemical remission.
Sections du résumé
BACKGROUND
BACKGROUND
Regarding the inconclusive results of previous investigations, this study aimed to determine the association between pathology, as a possible predictor, with remission outcomes, to know the role of pathology in the personalized decision making in acromegaly patients.
METHODS
METHODS
A retrospective cohort study was performed on the consecutive surgeries for growth hormone (GH) producing pituitary adenomas from February 2015 to January 2021. Seventy-one patients were assessed for granulation patterns and prolactin co-expression as dual staining adenomas. The role of pathology and some other predictors on surgical remission was evaluated using logistic regression models.
RESULTS
RESULTS
Among 71 included patients, 34 (47.9%) patients had densely granulated (DG), 14 (19.7%) had sparsely granulated (SG), 23 (32.4%) had dual staining pituitary adenomas. The remission rate was about 62.5% in the patients with SG and DG adenomas named single staining and 52.2% in dual staining groups. Postoperative remission was 1.53-folds higher in the single staining adenomas than dual staining-one (non-significant). The remission rate was doubled in DG group compared to two other groups (non-significant). By adjusting different predictors, cavernous sinus invasion and one-day postoperative GH levels decreased remission rate by 91% (95% CI: 0.01-0.67; p = 0.015) and 64% (95% CI: 0.19-0.69; p < 0.001), respectively. Responses to the medications were not significantly different among three groups.
CONCLUSION
CONCLUSIONS
Various pathological subtypes of pituitary adenomas do not appear to have a predictive role in estimating remission outcomes. Cavernous sinus invasion followed by one-day postoperative GH is the strongest parameter to predict biochemical remission.
Identifiants
pubmed: 34530798
doi: 10.1186/s12902-021-00850-2
pii: 10.1186/s12902-021-00850-2
pmc: PMC8447747
doi:
Substances chimiques
Human Growth Hormone
12629-01-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
186Informations de copyright
© 2021. The Author(s).
Références
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51
pubmed: 25356808
Endocr Relat Cancer. 2001 Dec;8(4):287-305
pubmed: 11733226
Endocr Rev. 2004 Feb;25(1):102-52
pubmed: 14769829
Eur J Endocrinol. 2018 Dec 1;:
pubmed: 30540560
Endocr J. 2012;59(3):221-8
pubmed: 22200580
J Clin Endocrinol Metab. 2013 Aug;98(8):3190-8
pubmed: 23737543
Acta Neurochir (Wien). 2014 Dec;156(12):2221-30; discussion 2230
pubmed: 25238988
Endocr Pract. 2019 Apr;25(4):379-393
pubmed: 30657362
J Neurosurg. 2018 Sep 14;131(1):147-153
pubmed: 30215558
J Clin Med. 2019 Nov 13;8(11):
pubmed: 31766255
J Clin Endocrinol Metab. 2010 Jul;95(7):3141-8
pubmed: 20410227
J Clin Endocrinol Metab. 2001 Sep;86(9):4072-7
pubmed: 11549628
J Neurol Surg B Skull Base. 2014 Feb;75(1):47-52
pubmed: 24498589
Neurosurg Focus. 2010 Oct;29(4):E2
pubmed: 20887127
Endocrine. 2015 May;49(1):231-41
pubmed: 25129651
J Clin Pathol. 2006 Dec;59(12):1245-53
pubmed: 17142570
Eur J Endocrinol. 2010 Oct;163(4):531-9
pubmed: 20688896
Clin Endocrinol (Oxf). 2012 Jan;76(1):96-102
pubmed: 21722151
Eur J Endocrinol. 1995 Dec;133(6):686-90
pubmed: 8548053
Pituitary. 2018 Feb;21(1):1-9
pubmed: 28849339
J Clin Endocrinol Metab. 2005 Nov;90(11):6290-5
pubmed: 16118335
Eur J Endocrinol. 2013 Mar 15;168(4):491-9
pubmed: 23288882
Endocr Pathol. 2017 Sep;28(3):228-243
pubmed: 28766057
Mod Pathol. 2018 Jun;31(6):900-909
pubmed: 29434339
Horm Metab Res. 2002 Mar;34(3):137-43
pubmed: 11972303
Pituitary. 2020 Oct;23(5):582-594
pubmed: 32602066
Pituitary. 2013 Dec;16(4):490-8
pubmed: 23184260
Eur J Endocrinol. 2012 May;166(5):797-802
pubmed: 22334636
Endocr Pathol. 2008 Summer;19(2):82-91
pubmed: 18629656
Eur J Endocrinol. 2008 Aug;159(2):89-95
pubmed: 18524797
Endocrinol Diabetes Metab Case Rep. 2016;2016:
pubmed: 27855229
Pituitary. 2017 Feb;20(1):84-92
pubmed: 27586499
Neuroendocrinology. 2006;83(3-4):161-5
pubmed: 17047379
Clin Endocrinol (Oxf). 2013 Feb;78(2):263-70
pubmed: 22783815
Hormones (Athens). 2014 Jan-Mar;13(1):95-103
pubmed: 24722132
J Med Life. 2015 Oct-Dec;8(4):411-5
pubmed: 26664461
Eur J Endocrinol. 2018 Mar;178(3):R89-R100
pubmed: 29339530
J Clin Endocrinol Metab. 2016 Nov;101(11):3888-3921
pubmed: 27736313
Endocr Relat Cancer. 2003 Dec;10(4):611-9
pubmed: 14713271
J Clin Endocrinol Metab. 2008 Jan;93(1):61-7
pubmed: 17971431